Sufficient Treatment of Peripheral Intervention by Cilostazol
Status:
Unknown status
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Recently, Nanto et al. reported that cilostazol effectively prevented restenosis in a
retrospective analysis of 121 femoropopliteal artery lesions in percutaneous transluminal
angioplasty (PTA) patients who had undergone PTA. In a prospective 3-year follow-up study in
127 patients with similar diseases, the patency rate was significantly higher in the
cilostazol group than in the ticlopidine group. It was also found that cilostazol markedly
inhibited restenosis during the first 1-year period following endovascular therapy when
restenosis is most frequently observed. In addition, there have been sporadic reports that
cilostazol was effective in preventing post-stenting restenosis in the coronary artery area.
Based on these results, this multicenter study is going to be conducted to prospectively
evaluate the usefulness of cilostazol in lower limb endovascular therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Kansai Rosai Hospital
Collaborator:
Association for Establishment of Ebvidence in Interventions